Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07280-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Kilian Kluge und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna…. Hauptthemen laut MEDLINE: Genomic Instability, Prostatic Neoplasms, Castration-Resistant, Circulating Tumor DNA, Radiopharmaceuticals. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Background
PSMA-targeted radioligand therapies (PSMA RLT) are an effective and safe option for metastatic castration-resistant prostate cancer, but responsive subtypes and their biomarkers are not fully defined.
Methods
Plasma samples for cell-free DNA (cfDNA) analysis were collected from 17 patients undergoing [¹⁷⁷Lu]Lu-PSMA-I&T. CfDNA underwent whole-genome sequencing to establish copy number variation (CNV) profiles and circulating-tumor DNA (ctDNA) levels and compared between prostate-specific antigen (PSA) response- and 1-year overall survival (1YOS) groups.
Results
Non-responders exhibited higher degrees of cfDNA CNV burden ( P = 0.048) and higher ctDNA levels ( P = 0.036) than responders. Both markers allowed for the differentiation of responses (AUC: 0.792, 0.806) and 1YOS (AUC: 0.778, 0.847).
Conclusion
Unresponsive patients exhibited higher levels of cfDNA genomic instability and ctDNA levels, warranting genome-wide CNV profiling studies next to targeted approaches for mechanistic radiobiological insights and their value as response biomarkers for PSMA RLTs. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria.
- Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, Vienna, Austria.
- Department of Pathology, Medical University of Vienna, Vienna, Austria.
- Department of Urology, Medical University of Vienna, Vienna, Austria.
- Department of Urology and Andrology, University Hospital Krems, Krems, Austria.
- Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
ORCID-Profile: Kilian Kluge, Marcus Hacker
Förderung
- Medical University of Vienna
Zitieren
APA
Kluge, K., Haberl, D., Haug, A., Kenner, L., Kramer, G., Shariat, S., Kumpf, K., & Hacker, M. (2025). Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07280-5
Vancouver
Kluge K, Haberl D, Haug A, Kenner L, Kramer G, Shariat S, et al. Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07280-5
BibTeX
@article{Kluge2025,
author = {Kluge, Kilian and Haberl, David and Haug, Alexander and Kenner, Lukas and Kramer, Gero and Shariat, Shahrokh and Kumpf, Katarina and Hacker, Marcus},
title = {Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07280-5}
}
EUVIMED